Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLORPRES vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLORPRES is a combination of clonidine (alpha-2 adrenergic agonist that reduces sympathetic outflow) and chlorthalidone (thiazide diuretic that inhibits sodium reabsorption in distal tubules).
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
One tablet (clonidine 0.1 mg/chlorthalidone 15 mg) orally once or twice daily; maximum 0.6 mg clonidine/90 mg chlorthalidone daily.
250 mg orally twice daily
Terminal elimination half-life is 4-6 hours; may be prolonged in renal impairment, requiring dose adjustment.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Clonidine: hepatic metabolism (CYP2D6); Chlorthalidone: excreted unchanged in urine.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal excretion accounts for approximately 50% of elimination, with 30% as unchanged drug and 20% as metabolites; biliary/fecal elimination accounts for about 10%.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Approximately 90% bound to plasma proteins, primarily albumin.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
0.8-1.0 L/kg, indicating extensive tissue distribution; higher Vd may correlate with prolonged effect.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral bioavailability is 60-70% due to first-pass metabolism; intravenous bioavailability is 100%.
70-90% (oral); 100% (IV).
Chlorthalidone is ineffective if GFR <30 m L/min; avoid use. Clonidine requires dose reduction when GFR <10 m L/min; start at 0.1 mg once daily.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment. Child-Pugh B: reduce clonidine dose by 25%. Child-Pugh C: avoid or use with extreme caution; clonidine may precipitate encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended for children; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start with clonidine 0.1 mg chlorthalidone 15 mg once daily; monitor for orthostatic hypotension, bradycardia, and electrolyte disturbances. Titrate slowly every 2 weeks.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Rebound hypertension with abrupt clonidine withdrawal,Hypokalemia due to chlorthalidone,Bradycardia and syncope,Renal impairment: monitor electrolytes
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to clonidine or chlorthalidone,Anuria,Severe bradycardia or heart block
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-sodium foods as they can counteract the antihypertensive effect. Limit alcohol intake. Chlorthalidone may cause potassium depletion; consider potassium-rich foods (bananas, oranges, spinach) unless contraindicated. Grapefruit juice may increase clonidine levels; avoid excessive intake.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Pregnancy Category C. First trimester: risk of fetal bradycardia, oligohydramnios, and growth restriction due to reduced placental perfusion. Second/third trimester: potential for neonatal hypotension, respiratory depression, and electrolyte disturbances. Avoid use in pregnancy unless benefit outweighs risk.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Excreted in breast milk. M/P ratio not established. Monitor infant for bradycardia, hypotension, and hypoglycemia. Use caution; alternative agents preferred.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Dose adjustments may be required due to increased plasma volume and metabolism. Start at lowest effective dose; titrate based on blood pressure response and fetal status. No established specific dose changes.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Clorpres (clonidine + chlorthalidone) combines central alpha-2 agonist with thiazide diuretic. Monitor for orthostatic hypotension, especially in elderly. Rebound hypertension upon abrupt clonidine discontinuation is dangerous; taper over 2-4 days. Chlorthalidone may cause hypokalemia; check potassium levels regularly. Avoid use in patients with history of depression or severe bradycardia.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take the medication exactly as prescribed, usually once daily in the morning to prevent nighttime urination.,Do not stop taking this medication suddenly; stopping abruptly can cause a severe rise in blood pressure.,Rise slowly from sitting or lying down to prevent dizziness or fainting.,Avoid alcohol, which can worsen side effects like dizziness and drowsiness.,Report signs of low potassium (muscle cramps, weakness, irregular heartbeat) or dehydration (excessive thirst, dry mouth, dark urine).
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLORPRES vs ALDOCLOR-250, answered by our medical review team.
CLORPRES is a Antihypertensive Combination that works by CLORPRES is a combination of clonidine (alpha-2 adrenergic agonist that reduces sympathetic outflow) and chlorthalidone (thiazide diuretic that inhibits sodium reabsorption in distal tubules).. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLORPRES and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLORPRES is: One tablet (clonidine 0.1 mg/chlorthalidone 15 mg) orally once or twice daily; maximum 0.6 mg clonidine/90 mg chlorthalidone daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLORPRES and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLORPRES is classified as Category C. Pregnancy Category C. First trimester: risk of fetal bradycardia, oligohydramnios, and growth restriction due to reduced placental perfusion. Second/third trimester: potential for . ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.